ESMO 2021 | Results from KEYNOTE-716: adjuvant therapy with pembrolizumab in high-risk stage II melanoma

Thomas Eigentler, MD, University of Tübingen, Tübingen, Germany, comments on the results of a key clinical trial presented at ESMO 2021, KEYNOTE-716 (NCT03553836). KEYNOTE-716 is a Phase III study evaluating the safety and efficacy of pembrolizumab compared to placebo in resected high-risk stage II melanoma. This trial demonstrated a significant improvement in recurrence-free survival (RFS) for patients in the pembrolizumab arm. The results from this trial will hopefully lead to the approval of this drug for patients with stage II melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.